RT Journal Article
SR Electronic
T1 Clinical presentation and differential splicing of <em>SRSF2, U2AF1</em> and <em>SF3B1</em> mutations in patients with Acute Myeloid Leukaemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.07.20016881
DO 10.1101/2020.01.07.20016881
A1 Stefanos A. Bamopoulos
A1 Aarif M. N. Batcha
A1 Vindi Jurinovic
A1 Maja Rothenberg-Thurley
A1 Hanna Janke
A1 Bianka Ksienzyk
A1 Julia Philippou-Massier
A1 Alexander Graf
A1 Stefan Krebs
A1 Helmut Blum
A1 Stephanie Schneider
A1 Nikola Konstandin
A1 Maria Cristina Sauerland
A1 Dennis Görlich
A1 Wolfgang E. Berdel
A1 Bernhard J. Woermann
A1 Stefan K. Bohlander
A1 Stefan Canzar
A1 Ulrich Mansmann
A1 Wolfgang Hiddemann
A1 Jan Braess
A1 Karsten Spiekermann
A1 Klaus H. Metzeler
A1 Tobias Herold
YR 2020
UL http://medrxiv.org/content/early/2020/01/10/2020.01.07.20016881.abstract
AB Previous studies have demonstrated that splicing factor mutations are recurrent events in hematopoietic malignancies. Their clinical characteristics and aberrant splicing patterns have been explored in myelodysplasia, however, their functional consequences in acute myeloid leukaemia are largely unknown. The aim of this study was the comprehensive clinical and functional analysis of mutations in the three most commonly afflicted splicing factor genes: SRSF2, U2AF1 and SF3B1. To this end, we examined the prognostic role of splicing factor mutations in two large independent cohorts, encompassing a total of 2678 acute myeloid leukaemia patients treated with intensive chemotherapy. The clinical analysis was complemented by RNA-sequencing of 246 patients to identify targets of splicing dysregulation. Results were validated in an additional RNA-sequencing dataset of 177 patients. Patients with splicing factor mutations show inferior relapse-free and overall survival, however, these mutations do not represent independent prognostic markers. Differential isoform expression analysis revealed a characteristic expression profile for each splicing factor mutation with a strong dysregulation of several isoforms. Furthermore, by establishing a custom differential splice junction usage pipeline we accurately detected aberrant splicing in splicing factor mutated samples. Mutated samples were characterized by predominantly decreased splice junction utilization of a large number of genes. A large proportion of differentially used spliced junctions were novel. Targets of splicing dysregulation included several genes with a known role in acute myeloid leukaemia. In SRSF2(P95H) mutants we further explored the possibility of a cascading effect through the dysregulation of the splicing pathway.Taken together, our findings suggest that splicing factor mutations does not represent independent prognostic markers. However, they do have genome-wide consequences on gene splicing leading to dysregulated isoform expression of several genes.Competing Interest StatementH.J. is a current employee of Roche Pharma AG, Grenzach-Wyhlen, Germany. The authors declare no competing financial interests.Funding StatementThis work is supported by a grant of the Wilhelm-Sander-Stiftung (no. 2013.086.2) and the Physician Scientists Grant (G-509200-004) from the Helmholtz Zentrum München to T.H. and the German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, Heidelberg, Germany). K.H.M., K.S. and T.H. are supported by a grant from Deutsche Forschungsgemeinschaft (DFG SFB 1243, TP A06 and TP A07). S.K.B. is supported by Leukaemia &amp; Blood Cancer New Zealand and the family of Marijanna Kumerich. A.M.N.B. is supported by the BMBF grant 01ZZ1804B (DIFUTURE).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data of this study is available, but German law restrictions apply to the availability of these data, which were used for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the local ethics committee. https://data.mendeley.com/datasets/7sg6bn8m74/draft?a=57983ef4-798a-4ade-ac94-8304628cf27a